Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196206 · ClinicalTrials.gov registry record · Phase 1
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
A Phase 1 study of Thrombosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT03196206: Completed Phase 1 study of Thrombosis, sponsored by Bristol-Myers Squibb.
NCT03196206 is a Phase 1 study of Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03196206, a Phase 1 study of Thrombosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
Primary Outcome
Measured by plasma concentration
Conditions Studied
Interventions
- DRUG BMS-986177
Study Locations (3)
Florida
- Clinical Pharmacology Of Miami Inc. - Miami
- Clinical Pharmacology of Miami LLC - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2018-03-04 |
| Phase | Phase 1 |
What the finished NCT03196206 record still lists
NCT03196206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which BMS-986177 is the first listed.
NCT03196206 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03196206 about?
NCT03196206 is a clinical study titled "Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment". Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
What is the current status of trial NCT03196206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-07-13. Estimated completion is 2018-03-04.
What conditions does trial NCT03196206 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT03196206?
The interventions under investigation include: BMS-986177 (DRUG).
Who is sponsoring clinical trial NCT03196206?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03196206 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03196206's enrollment target sits among peer trials
24 18th of 28 higher than 10 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
COMPLETED · Phase 1
-
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
COMPLETED · Phase 1
-
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
COMPLETED · Phase 1
-
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI